Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening
Hannah Shilling, Gerald Murray, Julia ML Brotherton, David Hawkes, Marion Saville, Terri Sivertsen, Ian Chambers, Jennifer Roberts, Annabelle Farnsworth, Suzanne M Garland, Jane S Hocking, John Kaldor, Rebecca Guy, Steph Atchison, Anna-Maria Costa, Monica Molano, Dorothy A Machalek
Vaccine | ELSEVIER SCI LTD | Published : 2020
INTRODUCTION: Australia has recently implemented major changes in cervical cancer prevention policies including introduction of primary human papillomavirus (HPV) screening starting at age 25, and replacement of the quadrivalent HPV vaccine with the nonavalent vaccine in the national school-based program. We assessed the feasibility and utility of conducting HPV testing in residual clinical specimens submitted for routine Chlamydia trachomatis screening, as a means of tracking HPV vaccine program impact among young sexually active women. METHODS: De-identified residual specimens from women aged 16-24 years submitted for chlamydia testing were collected from three pathology laboratories in Vi..View full abstract
Awarded by Commonwealth Department of Health HPV Surveillance Fund
This work is supported by the Commonwealth Department of Health HPV Surveillance Fund (Activity number 4-8FG4IWD). The funders had no role in study design, data collection, analyses, and interpretation of data, writing of the report, or in the decision to submit the article for publication.